Developing pharmaceutical technology tailored for patient needs
In the realm of drug delivery devices, a shift in focus is underway, steering away from idealized users and towards real patients. This approach, centred on empathy and usability, ensures that devices are not only technically effective but also cater to the lived experiences and diversity of those who will use them daily.
The core of this revolution lies in early, integrated, and human-centric development strategies. By involving device teams in drug development from the outset, alignment with drug properties and patient needs is ensured, reducing risks and enabling flexibility during clinical phases.
Integrated development plans, coordinating drug and device timelines, foster better communication and avoid misalignment between components. Cross-functional collaboration among drug developers, device engineers, regulatory experts, and end-user representatives is also crucial, allowing for knowledge sharing and early addressing of challenges.
Human-centric design principles are at the heart of this movement. These principles focus on real patient environments and capabilities, ensuring devices are simple, safe, intuitive, and respect patient dignity and independence. This includes designing for home use with clear instructions, robust safety features, and adaptability for varied user contexts such as different home environments and caregiver involvement.
Clinical and human factors validation studies, involving actual patient populations, are also integral to this approach. These studies capture real usability issues, injection pain, dose accuracy, and adverse reactions, ensuring devices are tailored to meet the needs of real patients.
Partnering with the right device developers and manufacturers is another key aspect. This partnership secures regulatory and quality management support tailored to real-world use and post-market device performance monitoring.
Innovation in support technologies, such as telehealth integration or companion digital apps, also plays a significant role. These technologies guide and support patients in real time, improving adherence and safety outside clinical settings.
The hardest part of design, as Andy Pidgeon, Head of Usability at 42 Technology, points out, is restraint. AI can personalize reminders, adjust timings, and suggest better techniques, but it must be optional and understandable to avoid losing trust from patients.
The ultimate goal is to help people take their medicine safely, confidently, and without hesitation. Simplicity is essential for some patients, as complexity can make treatment unmanageable for them. However, simplicity is not the opposite of innovation; rather, it is the highest form of it, as a great device hides its complexity, reduces steps, removes decisions, and offers reassurance.
A smart injector that helps a patient stick to their therapy without stress is a sign of real progress. A device that complicates the routine or leaves the patient feeling confused or watched has failed. If most patients choose the simpler option over the fancy version, it suggests that the original design may have solved the wrong problem.
Wearable injectors, infusing larger volumes of viscous drugs through a patch-like device, reduce the need for regular clinic visits. Skin sensors can prove adherence to remote monitors, but this offers little benefit to the patient.
When designing, it is important to consider whether a feature makes life easier or more confusing for the patient, and whether it can be optional or removed entirely. Designing with empathy involves asking about the user's goals, potential struggles, and feelings of confidence or fear.
The smartest device is not the one with the most features, but the one that knows when to stay out of the way. Optional features like connectivity or temperature sensing in platform devices should only be added when they benefit the user.
In the process of injecting, many patients create rituals and need clarity, preferring a single large button over multiple choices. Skin sensors can help prevent accidental misfires, but they may not always be necessary, and their added complexity should be justified.
In conclusion, the future of drug delivery devices lies in empathy and usability. By focusing on the needs of real patients, we can create devices that are not only effective but also simplify complex tasks, support adherence, and ultimately lead to better therapeutic outcomes.
Medical-condition specific devices, designed using medical-plastics and advances in technology, are being developed to improve health-and-wellness outcomes for patients. These devices, incorporating therapies-and-treatments into their design, are based on human-centric principles, ensuring usability, safety, and simplicity for patients.
Collaborative research in science, combining expertise from drug developers, device engineers, regulatory experts, and end-user representatives, is essential to create medical plastics products that cater to the diverse needs of patients. This collaborative approach streamlines clinical and human factors validation studies, ensuring the development of devices that are tailored to meet the needs of real patients.
